BridgeBio Pharma Announces Upcoming Presentations on ATTRibute-CM
BridgeBio Pharma, Inc. (NASDAQ: BBIO) has revealed its plans to share further analyses from the Phase 3 ATTRibute-CM trial of acoramidis, a treatment designed for patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). These presentations are set to take place at two major conferences: the European Society of Cardiology (ESC) Congress 2024 and the Heart Failure Society of America (HFSA) Annual Meeting 2024. These events will serve as an important venue for discussing significant data related to the clinical outcomes of acoramidis treatment.
ESC Congress Presentation Details
During the ESC Congress 2024, which will occur in late August, Dr. Mathew S. Maurer from Columbia University Irving Medical Center is scheduled to present a moderated poster discussing the increase in serum TTR levels linked to acoramidis treatment. This session is particularly pertinent as cardiac amyloidosis presents considerable diagnostic and therapeutic hurdles.
Key Session Information
The presentation, titled "Increase in Serum TTR Levels Observed with Acoramidis Treatment in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM and Its Open-Label Extension," will delve into insights from the trial and its clinical implications. It is set for Friday, August 30 at 10:00 am ET at Station 10 - Research Gateway.
HFSA Annual Meeting Details
Following the ESC Congress, the HFSA Annual Meeting 2024 will be held at the end of September, where Dr. Daniel P. Judge will present another important piece of research. His oral presentation, titled "Acoramidis Improves Clinical Outcomes in Patients with Transthyretin Amyloid Cardiomyopathy: A Post Hoc Recurrent Event Analysis of ATTRibute-CM," will examine data from the study that underscores the effectiveness of acoramidis in enhancing patient outcomes.
Relevant Presentation Information
This presentation is scheduled for Saturday, September 28 at 4:36 pm ET, and will take place at the Oral Abstract Stage within the Exhibit Hall. The insights shared during these sessions are expected to significantly enhance the understanding of ATTR-CM and the role of acoramidis in treatment.
BridgeBio's Commitment to Genetic Diseases
BridgeBio Pharma is committed to developing transformative therapies aimed at genetically driven diseases. Since its founding in 2015, the company has built a robust pipeline of development programs that range from early-stage research to advanced clinical trials. Their dedication to innovation in genetic medicine seeks to tackle the complex health challenges faced by patients.
Accessing Presentation Materials
For those interested in the details of these presentations, additional information will be made available on the Presentations page within the Investors section of the BridgeBio website after the events. This access will ensure that stakeholders remain informed about the latest findings and advancements from the company.
About BridgeBio Pharma, Inc.
The company aims to discover, create, test, and deliver new therapies that can transform the lives of patients suffering from genetic diseases. BridgeBio’s skilled team is dedicated to advancing the science of genetic medicine and enhancing treatment options available to patients across a variety of conditions.
Contact Information
If you have any inquiries regarding BridgeBio or their ongoing research, please reach out to:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
Frequently Asked Questions
What is the focus of BridgeBio Pharma?
BridgeBio Pharma is dedicated to developing innovative treatments specifically for genetic diseases.
What is the significance of the ATTRibute-CM trial?
The ATTRibute-CM trial evaluates the effectiveness of acoramidis in improving clinical outcomes for patients with ATTR-CM.
When are the presentations at ESC and HFSA scheduled?
The presentations are scheduled for August 30 at ESC and September 28 at HFSA.
Who are the presenters at the conferences?
Dr. Mathew S. Maurer will present at ESC, while Dr. Daniel P. Judge will speak at HFSA.
How can one access presentation materials?
Presentation materials will be accessible on the BridgeBio investor website following the events.